CELG Celgene Corp.

98.38-0.02 (-0.02%)
Close: September 16, 2019

98.390.01 (+0.01%)
After hours

Quote

Previous Close
$98.38
Day Range
$98.17-$98.69
52 Week Range
$58.59-$99.36
Volume
2,669,495
Avg Volume
3,258,843
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$69.73B
Enterprise Value (EV)
$83.97B
PE Ratio
13.12
EV/EBITDA
11.32
Price/Sales
4.56
Price/Book
11.32
PEG Ratio
0.40

Financials

Revenue
$15.29B
Gross Profit
$14.24B
EBITDA
$7.42B
EPS, ttm
$7.50
Profit Margin
26.46%
Revenue/Employee
$1.73M
Next Earnings Date
10/28/2019 (41 days)
Debt to Equity
329%
Debt
$20.28B
Cash
$6.04B
Net Debt
$14.24B

Performance

Beta
0.75
200 Day Moving Avg
$89.48
50 Day Moving Avg
$94.34
52 Week Change
12.82%
YTD Change
47.64%
1 Month Change
3.86%
3 Month Change
1.13%
6 Month Change
11.83%
1 Year Change
12.84%
2 Year Change
-18.49%
5 Year Change
32.83%

Share Count

Shares Outstanding
708.7M
Float
707.9M
Restricted Shares
829.2K
Restricted Shares, %
0.12%

Celgene Corp. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Mark J. Alles

Website: http://www.celgene.com

Description: Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Employees: 8,852